About this webinar
Patients who suffered an acute coronary syndrome have a very high risk of recurrent cardiovascular events. In addition to antiischemic and antithrombotic treatment, dyslipidaemia management in these patients is important since dyslipidaemia is one of the most important modifiable risk factors for atherosclerotic vascular disease. There is substantial evidence that LDL-C is causal in the disease and lowering LDL-C will prevent recurrent events.
The 2019 ESC/EAS Dyslipidaemia Guidelines have new and updated recommendations on management and follow up of patients who suffered an acute coronary syndrome.
This webinar comprises a 15-min presentation, in which Prof Tokgözoğlu will cover what the new Guidelines recommend, looking at assessment of risk, treatment goals and lipid modification strategies, and discussing the new evidence from recent clinical trials, followed by Q&A.
Take the opportunity to understand how the new Guidelines apply to your practice, and put your questions on this topic to Guidelines author Prof Tokgözoğlu in this interactive webinar.
This webinar is primarily suited to physicians in internal medicine, cardiology, diabetology, and endocrinology.
It is highly relevant to physicians in general practice, nurses and healthcare practitioners working in lipid clinics, in cardiovascular prevention, in diabetes and in many other clinics training care of patients with cardiovascular or metabolic diseases.
Others who will find the educational content of this webinar to be relevant include scientists working in cardiovascular epidemiology and in basic cardiovascular research, and persons employed in the pharma industry.
ABOUT THE PRESENTER
Prof Tokgözoğlu is Professor of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey. She is the current President of the European Atherosclerosis Society, having served in various roles on the Society’s Executive Committee since 2003, and as Chair of the 77th EAS Congress in İstanbul in 2008.
She has had a number of roles within European Society of Cardiology, including president of the ‘Atherosclerosis and Vascular Biology Working Group of the ESC’, on the boards of the ESC Fellowship and Training Committee, and ESC Education Committee. Prof. Tokgözoğlu has served on the board of the Prevention Association of the European Society of Cardiology between 2011-2016.
Prof. Tokgözoğlu has served in a number of executive roles within the Turkish Society of Cardiology, including Vice President and President, becoming the first female President of the society’s history.
Prof Tokgözoğlu has more than 400 publications, has authored 3 books and several book chapters. Prof. Tokgözoğlu has been an author on the EAS/ESC Dyslipidaemia Guidelines in 2011, 2016, and in 2019.
EAS has independently organised all matters related to these webinars, including content and presenters. We acknowledge financial support, in the form of an unrestricted educational grant, received from Sanofi and Regeneron in support of the programme.
President, European Atherosclerosis Society
The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of “advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”. For more than 50 years the Society’s exp...
Share this webinar